ACMG Annual Clinical Genetics Meeting 2024 Exhibit Theater Presentation

Exhibit Theater Presentation

The Fully Curated Human Genome –
Implications for Improved Clinical Diagnostics for both Known and Novel Variants

Diagnosing rare genetic diseases using gene panels, clinical exomes, and whole genome sequencing requires rigorous methods of data analysis and interpretation in molecular diagnostics labs. Curating the entire human genome at the gene and variant level will have a significant impact on our understanding of human genetics and how to apply these insights for clinical care. In particular, systematic identification of all published variants and expert review of associated evidence is a critical component in the resolution of variants of uncertain significance (VUS) and will enable more rapid and accurate variant interpretation.

In this talk, Chief Science Officer and Founder, Dr. Mark Kiel will convey how this curation will accelerate the field of genomics, patient diagnosis, and precision medicine development.

Following, Brittnee Jones, VP of Product Management, and Jeffrey Bissonnette, Senior Director of Genomic Curation, will deliver a comprehensive overview of Genomenon’s pioneering approach to curating the entire genome, providing insight into both known and novel variants.

Exhibit Theater Speakers
Mark J. Kiel, MD, PhD
Chief Scientific Officer & Co-Founder

Mark co-founded Genomenon in 2014 to close the evidence gap in rare disease and cancer. He holds an MD/PhD in Clinical Pathology from the University of Michigan and leads the company's scientific direction.

Jeffrey Bissonnette
Senior Director of Genomic Curation

With a background in genetic counseling, Jeffrey brings over a decade of experience in clinical genetics, variant interpretation, and software tools for variant analysis.

Brittnee Jones, PhD
Principal Technical Product Manager, AI & Data Engineering

Data-driven product manager with expertise in clinical genomics, global team building, and driving customer-focused products forward through market analysis and cross-functional collaboration.

2024 ACMG Annual Clinical Genetics Meeting
The World’s Most Comprehensive Source of Genomic Evidence

Mastermind accelerates variant interpretation with immediate insight into the full text of millions of scientific articles. Prioritize your search results by clinical relevance and find what you are looking for 5-10 times faster

Explore Mastermind CORE
Every Missing Genetic Variant is a Patient Your Label Doesn't Reach
  • Rare disease and precision oncology programs rely on evidence fragmented across millions of published articles and supplemental datasets.
  • Genomenon builds the custom real-world evidence your program needs.
  • AI-powered search. Expert scientific curation.
  • The result: a broader label, more eligible patients, and a regulatory filing your team can defend.
Request a custom evidence build for your program
speak with an expert